Vaccination responses in B‐cell‐depleted multiple sclerosis patients: The role of drug pharmacokinetics
- 9 September 2022
- journal article
- editorial
- Published by Wiley in European Journal of Neurology
- Vol. 29 (11), 3137-3138
- https://doi.org/10.1111/ene.15529
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- B‐cell repopulation dynamics and drug pharmacokinetics impact SARS‐CoV‐2 vaccine efficacy in anti‐CD20‐treated multiple sclerosis patientsEuropean Journal of Neurology, 2022
- Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273eLife, 2022
- Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or FingolimodNeurology Neuroimmunology & Neuroinflammation, 2022
- Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in ItalyEBioMedicine, 2022
- Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?Multiple Sclerosis and Related Disorders, 2021
- Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple SclerosisNeurology, 2021
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapyNature Medicine, 2021
- Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disordersJournal of Neurology, Neurosurgery & Psychiatry, 2021
- Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple SclerosisAnnals of Neurology, 2021
- Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesTherapeutic Advances in Neurological Disorders, 2021